• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

EpCAM and EGFR crosstalk in the development of resistance towards Cetuximab treatment in head and neck cancer.

作者信息

He Min, Gouda Mahesh, Gires Olivier

机构信息

Department of Otorhinolaryngology, Head and Neck Surgery, Grosshadern Medical Center, Ludwig-Maximilians-University, Munich, Marchioninistr. 15, 81377 Munich, Germany.

Department of Otorhinolaryngology, Head and Neck Surgery, Grosshadern Medical Center, Ludwig-Maximilians-University, Munich, Marchioninistr. 15, 81377 Munich, Germany.

出版信息

Oral Oncol. 2023 Aug;143:106465. doi: 10.1016/j.oraloncology.2023.106465. Epub 2023 Jun 21.

DOI:10.1016/j.oraloncology.2023.106465
PMID:37348447
Abstract
摘要

相似文献

1
EpCAM and EGFR crosstalk in the development of resistance towards Cetuximab treatment in head and neck cancer.上皮细胞粘附分子（EpCAM）与表皮生长因子受体（EGFR）在头颈部癌西妥昔单抗治疗耐药性形成中的相互作用
Oral Oncol. 2023 Aug;143:106465. doi: 10.1016/j.oraloncology.2023.106465. Epub 2023 Jun 21.
2
EpEX, the soluble extracellular domain of EpCAM, resists cetuximab treatment of EGFR-high head and neck squamous cell carcinoma.EpEX，EpCAM 的可溶性细胞外结构域，抵抗西妥昔单抗治疗 EGFR 高表达的头颈部鳞状细胞癌。
Oral Oncol. 2023 Jul;142:106433. doi: 10.1016/j.oraloncology.2023.106433. Epub 2023 May 24.
3
Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell lines.头颈部鳞状细胞癌细胞系中自分泌表皮生长因子受体配体的产生和西妥昔单抗的反应。
J Cancer Res Clin Oncol. 2012 Mar;138(3):491-9. doi: 10.1007/s00432-011-1127-5. Epub 2011 Dec 23.
4
Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines.MEHD7945A 单药或联合顺铂双重靶向表皮生长因子受体和 HER3 部分克服头颈部鳞状细胞癌细胞系对西妥昔单抗的耐药性。
Cancer Biother Radiopharm. 2017 Sep;32(7):229-238.
5
CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.CCI-779（替西罗莫司）在低表皮生长因子受体（EGFR）表达的头颈部鳞状细胞癌（HNSCC）细胞系中显示出增强的抗肿瘤活性，并且对顺铂或西妥昔单抗获得性耐药的细胞有效。
J Transl Med. 2015 Apr 1;13:106. doi: 10.1186/s12967-015-0456-6.
6
Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines.表皮生长因子受体状态以及Akt和p44/42丝裂原活化蛋白激酶（MAPK）通路的持续激活与西妥昔单抗在头颈部和结肠癌细胞系中的疗效相关。
J Cancer Res Clin Oncol. 2009 Mar;135(3):395-402. doi: 10.1007/s00432-008-0475-2. Epub 2008 Sep 24.
7
Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.头颈部鳞状细胞癌异种移植物对西妥昔单抗的敏感性与治疗诱导的 EGFR、pEGFR 和 pSrc 的减少有关。
J Oral Pathol Med. 2017 Oct;46(9):717-724. doi: 10.1111/jop.12545. Epub 2017 Jan 28.
8
AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer.AXL 调节神经调节蛋白 1 的表达，导致头颈部癌症对西妥昔单抗产生耐药性。
BMC Cancer. 2022 Apr 23;22(1):447. doi: 10.1186/s12885-022-09511-6.
9
Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K Polymorphism.头颈部癌症中的西妥昔单抗耐药性由 EGFR-K 多态性介导。
Cancer Res. 2017 Mar 1;77(5):1188-1199. doi: 10.1158/0008-5472.CAN-16-0754. Epub 2016 Dec 28.
10
Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck.头颈部鳞状细胞癌中的表皮生长因子受体抑制作用
Hematol Oncol Clin North Am. 2015 Dec;29(6):1011-32. doi: 10.1016/j.hoc.2015.07.007.

引用本文的文献

1
Regulation of the Function and Expression of EpCAM.上皮细胞黏附分子（EpCAM）功能与表达的调控
Biomedicines. 2024 May 20;12(5):1129. doi: 10.3390/biomedicines12051129.